comscoreAvastin Approved to Treat Breast Cancer

Avastin Approved to Treat Breast Cancer

The U.S. Food and Drug Administration has approved Avastin (chemical name: bevacizumab) to treat metastatic breast cancer.
Feb 25, 2008.This article is archived
We archive older articles so you can still read about past studies that led to today's standard of care.
Avastin (chemical name: bevacizumab), a targeted therapy medicine, has been approved by the U.S. Food and Drug Administration (FDA) to be used in combination with paclitaxel to treat women diagnosed with HER2-negative metastatic breast cancer. The approval also says that women who are to receive the Avastin-paclitaxel combination must not have received any other chemotherapy medicines to treat metastatic breast cancer. The medicine paclitaxel is sold commercially as Taxol and Abraxane.
Avastin already was approved by the FDA to treat advanced cancers of the lung, colon, and rectum.
Avastin is an antiangiogenesis medicine. This means that Avastin works by choking off cancer cells' blood supply so they can't survive. Anti means "in opposition to," angio means "blood vessel," and genesis means "beginning."
The FDA based its decision on research that showed women diagnosed with metastatic breast cancer who got both Avastin and Taxol had more time before the cancer got worse, compared to women who got only Taxol.
Still, the Avastin-Taxol combination hasn't been shown to improve overall survival, compared to Taxol alone. This could be because the benefits of adding Avastin to Taxol are too small to influence the overall survival of women diagnosed with metastatic breast cancer. Also, Avastin has a number of potentially serious side effects, including high blood pressure, nose bleeds, and extra protein in the urine. Avastin also may increase the risk of stroke and heart problems. These side effects might contribute to the lack of improvement in overall survival.
Before the FDA approved Avastin, 5 of 9 experts on an FDA panel reviewed research on Avastin and recommended the FDA not approve Avastin to treat metastatic breast cancer. The experts against approval were concerned that the potentially serious side effects of Avastin outweighed the benefits. The FDA doesn't have to follow the vote of its expert panel and didn't do so in this case.
If you've been diagnosed with metastatic breast cancer, your doctor may recommend Avastin. That recommendation will be based on information from published research and your doctor's experience with Avastin to treat other people with breast cancer, as well as YOUR unique situation.
As with any breast cancer treatment, ask your doctor about the benefits and possible side effects and risks of Avastin. Together, you and you doctor can make the best treatment choices for YOU.

— Last updated on February 22, 2022, 9:51 PM

Share your feedback
Help us learn how we can improve our research news coverage.